ORIC Pharmaceuticals, Inc.
$10.89
▲
18.93%
2026-04-21 08:40:02
www.oricpharma.com
NMS: ORIC
Explore ORIC Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.09 B
Current Price
$10.89
52W High / Low
$14.93 / $4.52
Stock P/E
—
Book Value
$3.9
Dividend Yield
—
ROCE
-36.81%
ROE
-41.27%
Face Value
—
EPS
$-1.47
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
104
Beta
1.36
Debt / Equity
1.94
Current Ratio
14.13
Quick Ratio
14.13
Forward P/E
-6.55
Price / Sales
—
Enterprise Value
$744.59 M
EV / EBITDA
-5.25
EV / Revenue
—
Rating
Strong Buy
Target Price
$21
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Black Diamond Therapeutics, Inc. | $3.05 | 7.84 | $175.3 M | — | 15.61% | 22.88% | $4.94 / $1.31 | $1.96 |
| 2. | Generate Biomedicines, Inc. | $12.12 | — | $1.59 B | — | -94.79% | -81.72% | $15.32 / $11 | $-12.24 |
| 3. | MiNK Therapeutics, Inc. | $12.82 | — | $63.66 M | — | 859.68% | 57.3% | $76 / $6.34 | $-3.02 |
| 4. | Zenas BioPharma, Inc. | $20.9 | — | $1.28 B | — | -65.85% | -1.36% | $44.6 / $8.09 | $4.44 |
| 5. | Silo Pharma, Inc. | $0.67 | — | $8.38 M | — | -61.55% | -74.57% | $1.19 / $0.22 | $0.47 |
| 6. | Bio Green Med Solution, Inc. | $1.19 | — | $6.54 M | 0.93% | 552.16% | -1.28% | $100.8 / $0.73 | $1.27 |
| 7. | Cadrenal Therapeutics, Inc. | $5.25 | — | $13.09 M | — | -491.51% | -2.6% | $17.5 / $4.21 | $1.17 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -34.55 M | -36.67 M | -39.06 M | -32.72 M | -39.57 M |
| Net Profit | -30.5 M | -32.59 M | -36.35 M | -30.02 M | -36.31 M |
| EPS in Rs | -0.27 | -0.29 | -0.32 | -0.27 | -0.32 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -143 M | -142.9 M | -110.78 M | -86.77 M |
| Net Profit | -129.47 M | -127.85 M | -100.7 M | -89.12 M |
| EPS in Rs | -1.16 | -1.14 | -0.9 | -0.8 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 408.89 M | 274.14 M | 252.01 M | 247.18 M |
| Total Liabilities | 24.53 M | 31.02 M | 27.92 M | 24.83 M |
| Equity | 384.36 M | 243.12 M | 224.09 M | 222.35 M |
| Current Assets | 288.47 M | 262.25 M | 212.6 M | 210.46 M |
| Current Liabilities | 20.42 M | 24.85 M | 20.46 M | 15.39 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -110.97 M | -112.66 M | -85.69 M | -75.14 M |
| Investing CF | -148.03 M | 22.14 M | -43.4 M | -109.25 M |
| Financing CF | 245.26 M | 126.55 M | 85.66 M | 25.23 M |
| Free CF | -111.68 M | -113.85 M | -86.54 M | -77.22 M |
| Capex | -0.71 M | -1.19 M | -0.85 M | -2.08 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -26.96% | -12.99% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.